2365 related articles for article (PubMed ID: 15691217)
21. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Channual J; Wu JJ; Dann FJ
Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
[TBL] [Abstract][Full Text] [Related]
22. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
23. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
Wong VK; Lebwohl MG
Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
[TBL] [Abstract][Full Text] [Related]
24. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.
Lemos LL; de Oliveira Costa J; Almeida AM; Junior HO; Barbosa MM; Kakehasi AM; Acurcio FA
Rheumatol Int; 2014 Oct; 34(10):1345-60. PubMed ID: 24728068
[TBL] [Abstract][Full Text] [Related]
25. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
26. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
27. [Biological agents in treatment of psoriatic arthritis].
Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
[TBL] [Abstract][Full Text] [Related]
28. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
[TBL] [Abstract][Full Text] [Related]
29. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
30. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
31. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
32. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
33. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
34. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
[TBL] [Abstract][Full Text] [Related]
35. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
36. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Atteno M; Peluso R; Costa L; Padula S; Iervolino S; Caso F; Sanduzzi A; Lubrano E; Del Puente A; Scarpa R
Clin Rheumatol; 2010 Apr; 29(4):399-403. PubMed ID: 20066450
[TBL] [Abstract][Full Text] [Related]
38. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin.
Braun J; Sieper J
BioDrugs; 2003; 17(3):187-99. PubMed ID: 12749755
[TBL] [Abstract][Full Text] [Related]
39. TNF-alpha inhibitors in dermatology.
Cordoro KM; Feldman SR
Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
[TBL] [Abstract][Full Text] [Related]
40. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
Mease P
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S116-21. PubMed ID: 12463460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
